Answers are grounded in this paper and cite their sources.
Review synthesizes genome-editing strategies for CAR-T cell therapy in EBV-associated nasopharyngeal carcinoma, highlighting translational barriers and genomic safety challenges.
Epstein‐Barr virus (EBV)‐associated nasopharyngeal carcinoma (NPC) remains a clinically challenging malignancy, particularly in recurrent or metastatic disease where durable responses to chemoradiotherapy and immune checkpoint blockade are limited. The viral aetiology of NPC provides a strong biological rationale for immune‐based treatment; however, translation of chimaeric antigen receptor (CAR) T‐cell therapy into this solid tumour setting is constrained by poor tumour trafficking, antigen heterogeneity, limited surface accessibility of EBV latent antigens, T‐cell exhaustion, and an immunosuppressive tumour microenvironment. This review critically evaluates the emerging therapeutic prospects of CRISPR‐engineered CAR‐T cell therapy for EBV‐associated NPC. It synthesises evidence on EBV latency biology, NPC immune evasion, solid‐tumour CAR‐T limitations, and genome‐engineering strategies including conventional CRISPR‐Cas9, base editing, prime editing, and double‐strand‐break‐sparing targeted integration. Particular attention is given to genotoxicity, chromosomal rearrangements, chromosome loss, bystander and off‐target editing, manufacturing heterogeneity, and the regulatory and biological barriers that currently separate technical feasibility from NPC‐specific clinical implementation. Available clinical evidence from checkpoint blockade, EBV‐specific adoptive T‐cell therapy, base‐edited CAR‐T cells in haematologic malignancy, and early CRISPR‐edited T‐cell trials supports the feasibility of immune and genetic redirection but does not establish efficacy of a clinically validated CRISPR‐engineered CAR‐T platform for NPC. Future development should prioritise surface‐accessible antigen validation, fit‐for‐purpose selection of editing technology, genomic safety, scalable manufacturing, and biomarker‐driven early‐phase trials.
No takes yet. Share an insight, caveat, or question.
Allehyani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: